Felix Korell (@FpkMd) header
Felix Korell (@FpkMd) profile picture

M.D., Research Fellow @MassGeneral @MarcelaMaus Lab. Focus: cellular immunotherapy, precision medicine, alloSCT @uniklinik_hd & @Schmitt_lab Tweets are my own

Boston
Joined January 2020
Photo by Felix Korell (@FpkMd)Photo by Felix Korell (@FpkMd)Photo by Felix Korell (@FpkMd)
Check out this must-read commentary from my good friend @EliDarnellMD and my mentor @MarcelaMaus on a study investigating the impact of TME on CART efficacy within the ZUMA7 trial doi.org/10.1016/j.xcrm.2024.… @MGHCancerCenter #WeekendReading
2
1
5
681
Must-read editorial on the amazing CARv3-TEAM-E study @MGHCancerCenter for glioblastoma led by @BryanDChoi & @MarcelaMaus, based on translational work from our Lab #CARTcells @OncoAlert
Science behind the Study: CAR T-Cell Therapy for Glioblastoma nej.md/49yGoKf #Neurology
2
12
2,231
aacrjournals.org/clincancerr… "Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma" I am delighted to have contributed to this outstanding work! A heartfelt congratulations to Marc Werli!
1
4
15
800
Hot off the press! Our work on second primary malignancies after commercial CAR T cells is out today in Blood. The FDA released scant information regarding the cases of T cell malignancies after CAR T therapy. Here, we provide more context by diving deep into the FDA Adverse Events Reporting System (FAERS). Read here 👉🏼doi.org/10.1182/blood.202402…
3
16
58
8,882
Clinical trial results from show "dramatic & rapid" regression of glioblastoma after next generation CAR T therapy at the Mass General Cancer Center with @MarcelaMaus, MD, director of the Cellular Immunotherapy Program. Learn more: spklr.io/6014Wf0K @NEJM
1
3
16
1,903
Felix Korell retweeted
A novel CAR T-cell therapy directed at EGFRvIII with a secretable EGFR T-cell engager produced rapid responses in three patients with recurrent glioblastoma, but the responses were transient in two of the three. Read the Brief Report for the full study: nej.md/3VnjUIq
84
5
287
49,321
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter! nej.md/3VnjUIq
33
176
26
826
141,011
Potential gamechanger! Huge congrats to @BryanDChoi @MarcelaMaus & team! @MGHCancerCenter
Today, @NEJM published our clinical study of a novel #CARTCell in patients with #Glioblastoma. Early results with CARv3-TEAM-E suggest safety and bioactivity. Special thanks to all collaborators @MGHNeurosurg and @MGHCancerCenter! nej.md/3VnjUIq
7
267
Felix Korell retweeted
#CARTcell all-star @MarcelaMaus shares her latest in novel CAR targets & limiting irAEs at #AACRbcd24. Highlighting need to harmonize single-cell correlative analyses OUT NOW as InFocus in @BCD_AACR w/ @njharlen: aacrjournals.org/bloodcancer… 1/2
1
3
4
690
Amazing to have this out now @eClinicalMed: our work on cardiotoxicity after CAR T cell therapy & utilizing biomarkers such as hs-cTnT. Thanks for the great collaboration between @Kardioonkologie - led by @LorenzLehmann &team - and @med5_ukhd! @uniklinik_hd #CARTcells
Happy to share our last collaborative work! Great job by @FpkMd and all co-workers! Cardiovascular side effects and predictive value of cardiac biomarker (e.g., hs-cTnT)in patients treated with CAR T cell therapies @uniklinik_hd @Kardioonkologie @AG40_DGK sciencedirect.com/science/ar…
2
13
720
Preclinical study in @CCR_AACR on a next generation mesothelin targeted CAR T cell modality in #PancreaticCancer Mesothelin CAR T-cells secreting anti-FAP/anti-CD3 molecules efficiently target pancreatic adenocarcinoma and its stroma Collaboration between @MGHCancerCenter & @hopkinskimmel aacrjournals.org/clincancerr…
13
34
5,294
Felix Korell retweeted
Thrilled to launch my lab @Uniklinikum_Wue & @Uni_WUE with @dfg_public Emmy Noether & @Myeloma_Society support. So grateful to @JKeithJoung, Vikram Pattanayak, @H_Einsele & Michael Hudecek. We develop new treatments for cancer patients using #CRISPR 2.0 & CAR-T technology.
17
6
5
105
14,245
AML is an evasive, multi-arm(ed) foe that needs to be disarmed by continuous translational research efforts to increase treatment for our patients. Here we review recent results and highlight future directions. febs.onlinelibrary.wiley.com…… @hi_stem_lab @amleppa @AlexWaclawiczek
2
7
34
1,990
Low risk of second tumor after CAR T-cell immunotherapy! Our research will reassure the scientific community, healthcare providers, and patients about the unmet positive outcomes of CAR T-cell immunotherapy! Fresh off the press @RuellaLab @PennMDForum @MarcoRuella
Profiling a case of secondary T cell lymphoma following anti-CD19 #CARTcells suggests this was not caused by CAR insertional mutagenesis, with analysis indicating low secondary TCL risk after treatment @guido_ghilardi @MarcoRuella @RuellaLab @PennMedicine nature.com/articles/s41591-0…
1
8
1
26
6,208
Felix Korell retweeted
2023: The rise of precision cellular therapies. In this Year in Review, I highlight 3 major advances set to transform the treatment of autoimmune and rheumatic diseases. From CAR-T cells to antigen-specific, precision immunotherapies. Link: rdcu.be/dvsaG
5
27
3
120
16,049
Venetoclax in myeloma: to B, or not to B | Blood | American Society of Hematology. Editorial by ⁦@RaabMarc⁩ on the role of t(11;14) plasma cell epigenetic & transcriptional plasticity in venetoclax resistance published by Paola Neri & @NoemieLeblay ashpublications.org/blood/ar…
5
17
43
4,654
Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL loom.ly/KqGp-cI #researchletter #immunobiologyandimmunotherapy
16
28
3,852
👀Another #ash2023 abstract reporting secondary malignancies post CAR T (clinical trial), and spoiler alert authors reporting not related to product. 1025 C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up "Second primary malignancy after C-CAR039 infusion were observed in 3 pts; 2 acute myeloid leukemia (AML) occurred at 2 and 10 months, and 1 Epstein-Barr virus-positive cytotoxic T-cell lymphoma was at 8 months, the tumor biopsy was tested with qPCR and CAR transgene was negative and none were related to C-CAR039" major h/t to the amazing @MaverickNY ash.confex.com/ash/2023/webp…
8
16
2,949
As my colleague Marcela Maus says @statnews "Assuming CAR-T therapy caused all 19 of these cases, that would put the incidence of “CAR-T secondary malignancy orders of magnitude less than standard cancer treatments" www-statnews-com.proxy.libra…
3
18
3
61
9,580